August 20, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.07.023

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial

Listen to this summary

This study aimed to compare the efficacy of niraparib, a PARP inhibitor, versus standard platinum-taxane chemotherapy as neoadjuvant treatment for patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer. The results showed that the overall response rate before interval debulking surgery was significantly lower with niraparib (31.6%) compared to platinum-taxane (70.6%), leading to the early closure of the trial for futility. The safety profiles of both treatments were consistent with previous studies, with no fatal serious adverse events reported.

Shannon N Westin, Jimmy Belotte, Brunella Felicetti, Vishvajit Aghera, Ahmed YoussefAgha, Evi Bakirtzi, Ana Godoy Ortiz, Arantzazu Barquín García, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng, Dan-Arin Silasi, Leslie S Bradford, Fernanda B Musa, John K Chan, Joyce F Liu, Luis Rojas-Espaillat

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play